Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort

Clinical Infectious Diseases

Volumn 60, Issue 1, 2015, Pages 143-153

  Rokx, Casper ^a   Fibriani, Azzania ^a   Van De Vijver, David A M C ^a   Verbon, Annelies ^a   Schutten, Martin ^a   Gras, Luuk ^b   Rijnders, Bart J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STICHTING HIV MONITORING   (Netherlands)

Author keywords

antiretroviral therapy; emtricitabine; HIV 1; lamivudine; virological failure

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; ISOLATION AND PURIFICATION; MIDDLE AGED; NETHERLANDS; PROCEDURES; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84969498061     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu763     Document Type: Conference Paper

References (31)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/ 9789241505727-eng.pdf. Accessed 22 May 2014.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Section F-8, Table 6. Available at: http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed 22 May 2014.
3. European AIDS Clinical Society. EACS guidelines. Version 7.0, October 2013. Available at: http://www.eacsociety.org/Portals/0/Guidelines- Online-131014.pdf. Accessed 22 May 2014.
4. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158:84-92.
5. Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003; 188:1652-8.
6. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-40.
7. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49-57.
8. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60.
9. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-40.
10. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74-8.
11. Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012; 54:862-75.
12. Svicher V, Alteri C, Artese A, et al. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 2010; 55:336-44.
13. Marcelin AG, Charpentier C, Wirden M, et al. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J Antimicrob Chemother 2012; 67:1475-8.
14. Maserati R, De Silvestri A, Uglietti A, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010; 24:1013-8.
15. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-56.
16. Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012; 9: e1001290.
17. Ford N, Shubber Z, Hill A, et al. Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One 2013; 8:e79981.
18. The Dutch HIV Monitoring Foundation. HIV monitoring report 2013. Available at: http://www.hiv-monitoring.nl/files/5913/8443/2799/ SHM-MonitoringReport2013.pdf. Accessed 22 May 2014.
19. The Dutch HIV Monitoring Foundation (SHM). Annual report 2012. Available at: http://www.hiv-monitoring.nl/index.php/download-file/ view/405/371/. Accessed 22 May 2014.
20. Stanford HIV Database. Algorithm on HIV mutations and drug susceptibility. Available at: http://hivdb.stanford.edu/. Accessed 7 May 2014.
21. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46:399-424.
22. Feng JY, Anderson KS. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 1999; 38:55-63.
23. Schinazi RF. Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr 2003; 34:243-5; author reply 245-6.
24. Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999; 13:2239-50.
25. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009; 63:380-8.
26. Towner W, Kerrigan H, LaRieve M, et al. Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV infected patients: a pilot study. In: Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 14-18 November 2004. Abstract P49.
27. Sanne I, van der Horst C, Shaw A, et al. Two randomized controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). In: XIV International AIDS Conference, Barcelona, Spain, 7-12 July 2002. Abstract 4432.
28. Darin K, Scarsi K, Meloni S, et al. Clinical and virological outcomes of six first line regimens in a large ART program in Nigeria. In: XVIII International AIDS Conference, Vienna, Austria, 18-23 July 2010. Abstract THPE0117.
29. Mulenga L, Muwango A, Moyo C, et al. Efficacy of tenofovir disoproxil fumarate/emtricitabine and tenofovir disoproxil/lamivudine both in combination with efavirenz in antiretroviral-naive, HIV-1 infected Zambians. In: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia. 30 June-3 July 2013. Abstract TULBPE18.
30. Benson CA, van der Horst C, Lamarca A, et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004; 18:2269-76.
31. Sterne JA, May M, Costagliola D, et al. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63.